SC-ENVIVA-FOREST-FUND
20.9.2022 18:04:36 CEST | Business Wire | Press release
The Enviva Forest Conservation Fund (the Fund) today announced the recipients of its 2022 grants. The projects funded this year will help conserve more than 3,000 acres and protect ecologically sensitive bottomland hardwood forests in the Virginia-North Carolina coastal plains.
Including those announced today, the Fund has awarded 29 projects totaling more than $3,100,000 in grants over the past seven years. An estimated 33,000 acres will be protected when these projects reach completion. The forests conserved as a part of the Fund help clean drinking water, purify the air, buffer structures from storms, and provide habitat for many species of wildlife, while at the same time, providing jobs and economic opportunity for rural families and private landowners.
“The fund is well on its way to achieving its initial goal to protect over 35,000 acres of sensitive bottomland hardwood forests across Virginia and South Carolina,” said Thomas Meth, President of Enviva. “With more than three years left in the program, the Fund is poised to partner with more and more diverse conservation groups as well as supersede our commitment to long-term investments in forest stewardship for generations to come.”
The 2022 Enviva Forest Conservation Fund grant recipients include:
The Tar River Land Conservancy: Tar River Land Conservancy aims to purchase the Bowers Tract, consisting of 244 forested acres and 60 acres of agricultural upland fields. Fifty-four percent (219 acres) of the property is situated within the 100-year-old floodplain of Swift Creek, a major tributary of the Tar River. Adjoining the property, Swift Creek provides a habitat for numerous rare, threatened, and endangered aquatic species, including the federally protected Carolina Madtom, Tar River Spiny Mussel, and Neuse River Waterdog.
Three Rivers Land Conservancy: Three Rivers Land Conservancy aims to acquire 440 acres of bottomland hardwood forest adjacent to the Little River and Uwharrie National Forest in Montgomery County, North Carolina. The Little River Buffer and Cliffs natural areas are located on the property. Federally endangered Northern Long Eared Bat and the threatened Oak Toad, Alewife, and Blue Back Herring are all present within this forest acreage.
The Virginia Outdoors Foundation: The Virginia Outdoors Foundation aims to acquire the Turner Tract which lies on the state scenic Nottoway River near Cary's Bridge. This tract contains 134 acres of bottomland hardwoods (111 acres of general hardwoods and 23 acres of Cypress-Tupelo) which will be designated as "old growth" as well as hundreds of acres of working forest. This land contributes to the protected corridor on the Nottoway River and its conservation will support the effort to protect this unique and fragile Virginia resource with a “National Wild and Scenic River” designation. The balance of the tract will remain in working forest and/or agricultural use.
The Conservation Fund: The Conservation Fund will protect 1,915 acres dominated by native bottomland hardwoods, forested wetlands, and loblolly pine along the Nottoway River in Sussex County, Virginia. This project will add to the corridor of protected land along the Nottoway River with 3.5 miles of frontage along the Nottoway where federally endangered Roanoke Logperch and Dwarf Wedge Mussel are found. The property also features 2.5 miles of frontage on Black Branch Swamp, where over 220 acres of forested wetlands and 400 acres of bottomland hardwoods reside. Sustainable forest management and restoration to native longleaf pine and pine savanna on the property will help create a habitat for endangered species such as the Red-Cockaded Woodpecker. Once transferred to the Virginia Department of Wildlife Resources, the property will be open for hunting, hiking, fishing, boating, and wildlife watching.
Ducks Unlimited: Ducks Unlimited aims to acquire a total of 292 acres in Bertie and Gates counties in North Carolina, under two separate tracts - the Crawford Tract and the Gasking Swamp Tract. The Crawford Tract is home to the Red-Cockaded Woodpecker and will expand the adjacent (on 3 sides) Chowan Swamp Game Land, which is located in one of the most important river basins for anadromous fishes in North Carolina. The Gasking Swamp Tract will expand the adjacent Bertie County Game Land, which helps protect portions of the Cashie River Swamps’ small creeks, floodplain wetlands, and Significant Natural Heritage Areas. These tracts provide important travel corridors for black bears along the Cashie River and are recognized as a “Global Important Bird Area.”
“The Endowment continues to support the efforts of the Enviva Forest Conservation Fund. These long-term investments promote conservation, biological diversity, and ecosystem sustainability in these areas of North Carolina and Virginia,” said Teal Edelen, Program Officer at the U.S. Endowment for Forestry and Communities. “These grants support sources of clean air and water, protect threatened wildlife and plant life, and provide great opportunities for recreation in these areas.”
About the Enviva Forest Conservation Fund
The Enviva Forest Conservation Fund is a $5 million, 10-year program established by Enviva in December 2015 to protect environmentally sensitive bottomland and wetland forests. Administered by the U.S. Endowment for Forestry and Communities, the Fund awards grants annually to nonprofit organizations and government agencies for conservation projects. Learn more at http://envivaforestfund.org.
About the U.S. Endowment for Forestry and Communities
The U.S. Endowment for Forestry and Communities is a not-for-profit public charity working collaboratively with partners in the public and private sectors to advance systemic, transformative, and sustainable change for the health and vitality of the nation’s working forests and forest-reliant communities. To learn more about the Endowment, please visit our website at www.usendowment.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220920006011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
